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Vapor Recovery Systems Can
Reduce Risks from MTBE
I would like to comment on the article on
methyl tertiary butyl ether (MTBE) in the
October issue of Environmental Health
Perspectives [105:1042-1043 (1997)].
After serving on a panel convened by
the U.S. EPA on epidemiological studies
needed for evaluation of possible health
risks ofMTBE as a fuel additive, I feel that
the article is quite informative and will no
doubt be useful for those contemplating
further use of oxygenated fuels. There are
two matters that I feel are ofsome impor-
tance, and about them the article is silent.
First, the report ofsymptoms from use
in Fairbanks, Alaska, which stimulated
much interest and concern, was associated
with two unusual circumstances. First,
because ofthe extreme cold weather, vehi-
cle use is aberrant during the winter in
Fairbanks; for example, car motors are left
running once they are started. Secondly,
the price offuel increased sharply with the
introduction of MTBE, so the public had
to realize that there was a change.
The second matter was made clear to
the panel, but not widely disseminated. It
consisted ofthe protection provided to dri-
vers and service station attendants by the
proper use ofapproved vapor recovery sys-
tems during the filling of gasoline tanks.
Because such systems also prevent expo-
sures to other fuel ingredients, which may
include a certain amount of benzene, for
example, they have an added value in
health protection from whatever hazards
exposure to gasoline mayproduce. In addi-
tion, they also prevent the emission of
hydrocarbons, which can be involved in
photochemical pollution. Your illustration
of filling a gas tank without an approved
vapor recovery system is most inappropri-
ate. The article's discussion of cancer risk
also omits the reference to the protection
such systems may provide.
I have advised the EPA that the univer-
sal requirement ofsuch vapor recovery sys-
tems would have several other benefits to
health and the environment, as well as
obviating much ofthe need for further epi-
demiological studies of cancer risks from
MTBE. There is broad experience with
such systems, and there are abundant mea-
surements to support this position.
John R. GoIdsmith




There is currently much debate as to which
in vivo tests should be selected for the
detection of adverse effects of endocrine
disruptors in test animals. As coauthors ofa
much-cited article in EnvironmentalHealth
Perspectives (1), which described small (but
significant) decreases in testicular weight of
adult rats that had been exposed develop-
mentally to either of two environmental
estrogens, we would like to bring certain of
our experiences to the attention of readers
of EHP and to those involved in framing
and implementing regulatory guidelines in
this area. *
In our original paper, we described
small but repeatable effects of gestational
and lactational exposure to octylphenol
(OP) or butyl benzyl phthalate (BBP) on
adult testicular weight and daily sperm
production in rats. Two subsequent studies
by others (2,3), both ofwhich were more
detailed than our own, have failed to find
any effect ofBBP, despite using very simi-
lar or identical protocols to those used by
us. We were asked, and agreed, to help in
the design ofboth ofthese studies, and we
are convinced that every effort was made
to truly replicate our original experiments,
including the inclusion of a positive effect
control group exposed to diethylstibestrol
(DES). Though none of us involved in
these studies is able to offer an explanation
for the differences in results obtained, the
inconsistency in effect of BBP in these
studies should at least give us all pause for
thought. We would like to add to this by
reporting other recent experiences of ours
that we think have an important bearing
on the reproducibility of results based on
measurement ofadult testis weight and the
design and interpretation ofany test using
this endpoint as an indicator ofan adverse
effect of developmental exposure to hor-
monally active chemicals.
Approximately 9 months after comple-
tion of our study that was published in
EHP, testicularweights and bodyweights in
control (untreated/vehicle-treated) animals
in our breeding colony began to decline
over a period of months. eventually reach-
ing a nadir when the mean ± standard devi-
ation (SD) oftestis weight for 36 litters was
1,828 ± 121 mg, compared with the figures
of 1,968 ± 163, 2,014 ± 155, and 1,954 ±
118 mg reported in the three experiments
in our earlier study (1). This temporal
decrease in absolute testis weight in control
animals was of comparable magnitude to
the most severe treatment effect reported in
our paper in EHP (1,750 ± 180 and 1,847
± 157 mg in Studies 2 and 3, respectively)
(1), which resulted from developmental
exposure to DES that had been used as a
positive effect control. The decrease in testis
weight in controls over time is unexplained,
but did follow a permanent change in water
supply to our animal facility. In the last 18
months or so, testicular weights in control
animals in our colony have returned pro-
gressively toward the original values and
have now stabilized at levels comparable to
those we described (1) (1,956 ± 124 mg in
the most recent 29 litters).
During the period when control testic-
ular weights were low, developmental
exposure of rats to OP (1 mg/1 drinking
water), using an identical protocol to that
used in Study 3 in our earlier study (1),
failed to cause any significant decrease in
testis weight; indeed, weights were
increased by 7% (1,824 ± 79 mg in con-
trols, n = 7 litters; 1,950 ± 173 mg in OP-
treated, n = 15 litters; p<0.1 >0.05). In a
subsequent study undertaken when control
testis weights had recovered, we were able
to confirm a significant effect of DES (50
pg/l drinking water) on absolute testis
weight (1,903 ± 146 mg, n = 10 DES-
exposed litters; 2,050 ± 84 mg, n = 12 con-
trol litters; p<0.01) although when
expressed relative to body weight, this dif-
ference disappeared completely (DES: 4.52
± 0.30 mg/g body weight; Controls 4.51 ±
0.22; p >0.1). This again contrasts with
our original study (though this used 100
pg/l DES). A similar divergence in effect of
DES on absolute and relative testis weights
was also found in the study by Nair and
Jekat (3), whereas Ashby et al. (2) found a
significant reduction in both absolute and
relative testis weights after developmental
exposure to DES. This inconsistency in the
effects of DES occurred despite the fact
that all three studies used the same dose
level (50 pg/1) ofDES. These findings add
to growing awareness that endocrine dis-
ruption data may be difficult to reproduce
in different laboratories or between differ-
ent studies (4), although the reason for
these inconsistencies remains obscure.
We are unable to offer an explanation
for either the fall/recovery in testicular
weights in our control animals or for our
failure to obtain similar effects on testis
weight/relative testis weight after exposure to
OP, and possibly even DES, as we reported
originally. We remain confident in thevalid-
ity of our original published observations,
which we consider to fulfill all fundamental
scientific criteria with regard to numbers of
animals, repeatability offindings, recording
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